Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-059: Pembrolizumab in Advanced Gastric Cancer
NCT02335411Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Adverse Events at 65 months, Number of Participants Discontinuing Study Drug Due to AEs at 52 months and 2 more. Started Feb 2015; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02335411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335411.